Combining capabilities to grow: Navitas acquires KAI Research

By Maggie Lynch

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags Clinical trials Clinical research Clinical trial management Fda Nih Cdc Africa North america

Navitas has acquired KAI Research to expand its trial site footprint in North America and Africa as well as bolster its ability to manage clinical trials in a number of research areas.

Based in the US, KAI will provide Navitas will its existing relationships with clinical sites as well and its network of service providers in the US and in Africa. According to a spokesperson for Navitas, KAI will continue to work with the US government through clinical research contracts in areas of emergent and epidemic infectious diseases with a priority on the African continent supported by partners and sites throughout Africa.

The spokesperson added that through this agreement Navitas’ ability to interact with KAI’s network will put the company in a “unique standpoint in serving federal agenices like the US Food and Drug Administration (FDA), National Institute of Health (NIH), Center for Disease Control (CDC), and Department of defense.”

Per the acquisition, Navitas will also obtain KAI’s e-clinical solutions and patient registries which will enable the company to expand its Phase II and III capabilities in North America and add to its offerings in Europe.

The spokesperson added, “The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets.  Combining these operational and TA capabilities with our proprietary AI driven OneClincial platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us

Products

View more

Webinars